Covid 19 Clinical Trials

To date there is no brain imaging and olfactory data available in COVID-19 positive patients with anosmia. By describing the pathophysiological characteristics underlying the olfactory symptoms and clinical characteristics of COVID-19 infection, the study investigators wish to compare the MRI aspects obtained in COVID-19 patients with and without anosmia, in the absence of other underlying neurological disorders.

NCT04408391 Covid-19 Anosmia Other: Brain MRI scan

MeSH:Olfaction Disorders

HPO:Anosmia

Primary Outcomes

Description: MRI; Voxels

Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia

Time: Day 0

Secondary Outcomes

Description: MRI; Voxels

Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia

Time: Month 3

Description: MRI; Voxels

Measure: Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; voxels, value between 0-1

Measure: Fractional anisotropy between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; voxels, value between 0-1

Measure: Fractional anisotropy between COVID-19 patients with and without anosmia

Time: Month 3

Description: MRI; mm2/s

Measure: Mean diffusivity between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; mm2/s

Measure: Mean diffusivity between COVID-19 patients with and without anosmia

Time: Month 3

Description: MRI; mm2/s

Measure: Radial diffusivity between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; mm2/s

Measure: Radial diffusivity between COVID-19 patients with and without anosmia

Time: Month 3

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Day 0

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Day 8

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Month 1

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Month 2

Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale (cut-offs: strang (>80), moderate (40-80), attenuated (<40)

Measure: Ability to detect odor

Time: Day 0

Description: Patient asked to describe whether a pinch of sugar on their tongue taste sweet or salty

Measure: Ability to taste a pinch of sugar

Time: Day 0

Description: MRI: absence/presence

Measure: Presence of thrombotic and hemorrhagic lesions

Time: Day 0

Description: MRI: absence/presence

Measure: Presence of thrombotic and hemorrhagic lesions

Time: Month 3

Description: Short Ti Inversion Recovery (STIR); presence/absence

Measure: Presence of lesions with hyperintensity

Time: Day 0

Description: Short Ti Inversion Recovery (STIR); presence/absence

Measure: Presence of lesions with hyperintensity

Time: Month 3

Description: beta voxels

Measure: Projection network analysis of all patients

Time: Day 0

Description: beta voxels

Measure: Projection network analysis of all patients

Time: Month 3

Description: beta voxels

Measure: Blinded independent component analysis of all patients

Time: Day 0

Description: beta voxels

Measure: Blinded independent component analysis of all patients

Time: Month 3

Description: beta voxels

Measure: default mode network analysis of all patients

Time: Day 0

Description: beta voxels

Measure: default mode network analysis of all patients

Time: Month 3

Description: beta voxels

Measure: executive control network analysis of all patients

Time: Day 0

Description: beta voxels

Measure: executive control network analysis of all patients

Time: Month 3

CovidResearchTrials by Shray Alag

Covid 19 Research using Clinical Trials (Home Page)

Brain MRI scanWiki

Developed by Shray Alag

Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (0)

Correlated MeSH Terms (1)

Correlated HPO Terms (1)

Clinical Trials

1 Descriptive Pilot Study of Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia

NCT04408391 Covid-19 Anosmia Other: Brain MRI scan

MeSH:Olfaction Disorders

HPO:Anosmia

Primary Outcomes

Secondary Outcomes

Related HPO nodes (Using clinical trials)

HP:0000458: Anosmia

Genes 67

Protein Mutations 0

SNP 0